These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38779718)

  • 1. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.
    Wang Q; Guo Y; Schwanz LT; Mellis IA; Sun Y; Qu Y; Urtecho G; Valdez R; Stoneman E; Gordon A; Wang HH; Ho DD; Liu L
    Emerg Microbes Infect; 2024 Dec; 13(1):2359004. PubMed ID: 38779718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.
    Wang Q; Mellis IA; Ho J; Bowen A; Kowalski-Dobson T; Valdez R; Katsamba PS; Wu M; Lee C; Shapiro L; Gordon A; Guo Y; Ho DD; Liu L
    Emerg Microbes Infect; 2024 Dec; 13(1):2402880. PubMed ID: 39259045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
    Meng B; Abdullahi A; Ferreira IATM; Goonawardane N; Saito A; Kimura I; Yamasoba D; Gerber PP; Fatihi S; Rathore S; Zepeda SK; Papa G; Kemp SA; Ikeda T; Toyoda M; Tan TS; Kuramochi J; Mitsunaga S; Ueno T; Shirakawa K; Takaori-Kondo A; Brevini T; Mallery DL; Charles OJ; ; ; ; Bowen JE; Joshi A; Walls AC; Jackson L; Martin D; Smith KGC; Bradley J; Briggs JAG; Choi J; Madissoon E; Meyer KB; Mlcochova P; Ceron-Gutierrez L; Doffinger R; Teichmann SA; Fisher AJ; Pizzuto MS; de Marco A; Corti D; Hosmillo M; Lee JH; James LC; Thukral L; Veesler D; Sigal A; Sampaziotis F; Goodfellow IG; Matheson NJ; Sato K; Gupta RK
    Nature; 2022 Mar; 603(7902):706-714. PubMed ID: 35104837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
    Cele S; Jackson L; Khoury DS; Khan K; Moyo-Gwete T; Tegally H; San JE; Cromer D; Scheepers C; Amoako DG; Karim F; Bernstein M; Lustig G; Archary D; Smith M; Ganga Y; Jule Z; Reedoy K; Hwa SH; Giandhari J; Blackburn JM; Gosnell BI; Abdool Karim SS; Hanekom W; ; ; von Gottberg A; Bhiman JN; Lessells RJ; Moosa MS; Davenport MP; de Oliveira T; Moore PL; Sigal A
    Nature; 2022 Feb; 602(7898):654-656. PubMed ID: 35016196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination.
    Wang M; Zhang L; Li Q; Wang B; Liang Z; Sun Y; Nie J; Wu J; Su X; Qu X; Li Y; Wang Y; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):18-29. PubMed ID: 34818119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains.
    Starr TN; Greaney AJ; Stewart CM; Walls AC; Hannon WW; Veesler D; Bloom JD
    PLoS Pathog; 2022 Nov; 18(11):e1010951. PubMed ID: 36399443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad Neutralization Capacity of an Engineered Thermostable Three-Helix Angiotensin-Converting Enzyme 2 Polypeptide Targeting the Receptor-Binding Domain of SARS-CoV-2.
    Cavazzini D; Levati E; Germani S; Ta BL; Monica L; Bolchi A; Donofrio G; Garrapa V; Ottonello S; Montanini B
    Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring New COVID-19 Incertitude: JN.1 Variant- JN.1: The Queer Bird among Omicron Sublineages.
    Ray SK; Mukherjee S
    Infect Disord Drug Targets; 2025; 25(1):e270624231369. PubMed ID: 38939989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice.
    Hurst JR; Naghibosadat M; Budowski P; Liu J; Samaan P; Budiman F; Kurtesi A; Qi F; Menon H; Krishnan R; Abioye J; Gingras AC; Ostrowski M; Orozco NM; Kozak RA
    PLoS One; 2024; 19(12):e0314061. PubMed ID: 39625929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies.
    Jiang W; Jiang Y; Sun H; Deng T; Yu K; Fang Q; Ge H; Lan M; Lin Y; Fang Z; Zhang Y; Zhou L; Li T; Yu H; Zheng Q; Li S; Xia N; Gu Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2406300. PubMed ID: 39470577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies.
    Nan X; Li Y; Zhang R; Wang R; Lv N; Li J; Chen Y; Zhou B; Wang Y; Wang Z; Zhu J; Chen J; Li J; Chen W; Zhang Q; Shi X; Zhao C; Chen C; Liu Z; Zhao Y; Liu D; Wang X; Yan LT; Li T; Zhang L; Yang YR
    Nat Commun; 2024 Dec; 15(1):10578. PubMed ID: 39632831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic study of the transmission pattern of the SARS-CoV-2 omicron variant.
    An K; Yang X; Luo M; Yan J; Xu P; Zhang H; Li Y; Wu S; Warshel A; Bai C
    Proteins; 2024 Jun; 92(6):705-719. PubMed ID: 38183172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo.
    Tsugawa Y; Furukawa K; Ise T; Takayama M; Ota T; Kuroda T; Shano S; Hashimoto T; Konishi H; Ishihara T; Sato M; Kamada H; Fukao K; Shishido T; Yoshikawa M; Takahashi T; Nagata S
    PLoS One; 2024; 19(12):e0300297. PubMed ID: 39621673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
    Zhang L; Cui Z; Li Q; Wang B; Yu Y; Wu J; Nie J; Ding R; Wang H; Zhang Y; Liu S; Chen Z; He Y; Su X; Xu W; Huang W; Wang Y
    Commun Biol; 2021 Oct; 4(1):1196. PubMed ID: 34645933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines.
    Liang CY; Raju S; Liu Z; Li Y; Asthagiri Arunkumar G; Case JB; Scheaffer SM; Zost SJ; Acreman CM; Gagne M; Andrew SF; Carvalho Dos Anjos DC; Foulds KE; McLellan JS; Crowe JE; Douek DC; Whelan SPJ; Elbashir SM; Edwards DK; Diamond MS
    Nature; 2024 Jun; 630(8018):950-960. PubMed ID: 38749479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
    Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G
    Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
    Yuan M; Huang D; Lee CD; Wu NC; Jackson AM; Zhu X; Liu H; Peng L; van Gils MJ; Sanders RW; Burton DR; Reincke SM; Prüss H; Kreye J; Nemazee D; Ward AB; Wilson IA
    Science; 2021 Aug; 373(6556):818-823. PubMed ID: 34016740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.